You are here

SPIRIT: Higher MMR Rate With Imatinib/Peginterferon vs Imatinib Alone & Imatinib/Cytarabine in Patients with Newly Diagnosed CML

CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting* *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

SPIRIT: Higher MMR Rate With Imatinib/Peginterferon vs Imatinib Alone and Imatinib/Cytarabine in Patients with Newly Diagnosed CP-CML
Posting Date: December 09, 2008

Interim analysis of the STI571 Prospective Randomized Interferon Trial (SPIRIT) from the French Chronic Myeloid Leukemia (CML) Group: multicenter, open-label, prospective, randomized, phase III trial
Summary of Key Conclusions
Preliminary analysis of 4 imatinib-based regimens finds that significantly more patients with newly diagnosed chronic-phase CML attained major molecular response with imatinib/peginterferon alfa-2a combination therapy vs standard-dose imatinib after 12 months
Rates of imatinib discontinuation comparable across all 4 arms
Higher incidence of grade 3/4 toxicity observed with higher-dose imatinib and imatinib combination therapies vs standard-dose imatinib

....more